Soleno Therapeutics, Inc. (NASDAQ:SLNO) Shares Purchased by Geode Capital Management LLC

Geode Capital Management LLC raised its holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO) by 10.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 599,119 shares of the company’s stock after buying an additional 58,823 shares during the quarter. Geode Capital Management LLC’s holdings in Soleno Therapeutics were worth $26,937,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of SLNO. State Street Corp boosted its position in shares of Soleno Therapeutics by 14.2% in the third quarter. State Street Corp now owns 1,142,169 shares of the company’s stock worth $57,668,000 after acquiring an additional 142,033 shares during the last quarter. Barclays PLC boosted its holdings in shares of Soleno Therapeutics by 149.3% in the 3rd quarter. Barclays PLC now owns 52,545 shares of the company’s stock valued at $2,652,000 after purchasing an additional 31,467 shares during the last quarter. Teachers Retirement System of The State of Kentucky purchased a new stake in shares of Soleno Therapeutics during the 3rd quarter valued at $656,000. Virtu Financial LLC acquired a new stake in Soleno Therapeutics during the third quarter worth about $490,000. Finally, JPMorgan Chase & Co. raised its holdings in Soleno Therapeutics by 35.8% in the third quarter. JPMorgan Chase & Co. now owns 13,915 shares of the company’s stock valued at $703,000 after buying an additional 3,666 shares during the period. Institutional investors and hedge funds own 97.42% of the company’s stock.

Soleno Therapeutics Stock Up 0.1 %

Shares of SLNO opened at $69.98 on Friday. Soleno Therapeutics, Inc. has a 52-week low of $36.61 and a 52-week high of $74.00. The firm has a market cap of $3.21 billion, a price-to-earnings ratio of -21.08 and a beta of -2.29. The business’s 50 day moving average is $54.76 and its two-hundred day moving average is $51.93.

Soleno Therapeutics (NASDAQ:SLNO) last posted its quarterly earnings results on Wednesday, March 5th. The company reported ($1.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.41). On average, equities analysts expect that Soleno Therapeutics, Inc. will post -3.72 earnings per share for the current fiscal year.

Insider Activity

In other news, VP Michael F. Huang sold 14,583 shares of Soleno Therapeutics stock in a transaction that occurred on Thursday, March 27th. The stock was sold at an average price of $69.51, for a total value of $1,013,664.33. Following the completion of the transaction, the vice president now owns 36,817 shares in the company, valued at approximately $2,559,149.67. This trade represents a 28.37 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Patricia C. Hirano sold 128,653 shares of the company’s stock in a transaction that occurred on Thursday, March 27th. The shares were sold at an average price of $68.32, for a total value of $8,789,572.96. Following the sale, the insider now directly owns 55,789 shares in the company, valued at approximately $3,811,504.48. This represents a 69.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 942,672 shares of company stock worth $64,058,781. 12.30% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Guggenheim reissued a “buy” rating and issued a $81.00 target price (up previously from $70.00) on shares of Soleno Therapeutics in a research note on Friday, March 28th. HC Wainwright reissued a “buy” rating and set a $100.00 price target on shares of Soleno Therapeutics in a research report on Tuesday. Stifel Nicolaus upped their price target on Soleno Therapeutics from $74.00 to $108.00 and gave the stock a “buy” rating in a report on Friday, March 28th. Robert W. Baird lifted their price objective on shares of Soleno Therapeutics from $72.00 to $102.00 and gave the company an “outperform” rating in a research note on Thursday, March 27th. Finally, UBS Group set a $105.00 target price on shares of Soleno Therapeutics in a research note on Thursday, March 27th. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Soleno Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $99.63.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.